Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $34
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to $34.
Baird analyst Colleen Kusy maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $14 to $34.